The company has secured U.S. patents and achieved European Union certification for the TRACER 1000, the world's first mass-spec Explosives Trace Detector used in airports worldwide. Astrotech's technology is ruggedized, rapid, simple to use and customizable with hands-free calibration and tuning. The company is positioned in growing security screening and specialized instrumentation markets with diverse applications.
Cyborg Score Rationale
The company has negative EBITDA of -$12.1M with TTM revenue of $2.0M and is generating minimal commercial traction despite differentiated technology. Structural challenges include tiny market capitalization, persistent losses, and limited analyst coverage, though the company possesses valuable IP and products with genuine market applications.
Top Insights
Diversified product portfolio spanning TRACER 1000 explosive/narcotics detection, AgLAB-1000 for cannabis quality control, BreathTest-1000 for disease screening, and EN-SCAN for environmental contamination analysis.
1st Detect subsidiary generated $750,000 in revenue during fiscal year ended June 30, 2023. Revenue base remains extremely small for a public company.
Share price has been volatile over the past 3 months with weekly volatility of 11%, higher than 75% of US stocks.
The company's intellectual property includes 18 granted patents along with extensive trade secrets.
Named Competitors
Explosives Trace Detection Systems — Global leader in security screening and threat detection
Gas Chromatography-Mass Spectrometry — Diversified analytical instrumentation provider
Breath Analysis Platforms — Breath biomarker analysis for disease detection
Recent Developments
(August 2025) Appointed Nihanth Badugu as Chief Operating Officer
(August 2025) Introduced EN-SCAN product line for air, water, and soil contamination analysis
(May 2025) Appointed Jennifer Cañas as Chief Financial Officer; reported Q3 FY2025 financial results